ArticleDrugs2022

Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.

Sahil Khanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.